Osborne Clarke advised Sofinnova Ventures and Ysios Capital in the USD 30 million Series B Financing of BioClin Therapeutics which also included existing investors HealthCap, Life Sciences Partners (LSP), and Tekla Capital Management.

BioClin Therapeutics is a privately-held clinical stage drug development company developing a first-in-class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody in areas of high unmet medical need.

The Osborne Clarke Netherlands team was led by Partner Herke van Hulst, who was assisted by Senior Associate Geoffrey Beurskens.